Selected research
Industry Growth & Trends
Global Febrile Neutropenia Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Febrile Neutropenia market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Febrile Neutropenia is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Febrile Neutropenia is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Febrile Neutropenia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Febrile Neutropenia market include BeyondSpring Inc., Eli Lilly and Company, Taiho Pharmaceutical Co., Ltd., Amgen Inc., Xenetic Biosciences, Inc. (XBIO), USV Private Limited, Richter Gedeon Nyrt., Hospira, Inc. and Aequus BioPharma, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Febrile Neutropenia market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Febrile Neutropenia market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Febrile Neutropenia market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Febrile Neutropenia.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Febrile Neutropenia market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Febrile Neutropenia Market by Company
BeyondSpring Inc.
Eli Lilly and Company
Taiho Pharmaceutical Co., Ltd.
Amgen Inc.
Xenetic Biosciences, Inc. (XBIO)
USV Private Limited
Richter Gedeon Nyrt.
Hospira, Inc.
Aequus BioPharma, Inc.
Febrile Neutropenia Segment by Type
Filgrastim Biosimilars
Pegfilgrastim
Pegfilgrastim Biosimilars
Vancomycin Hydrochloride
Others
Febrile Neutropenia Segment by Application
Hospitals
Clinics
Others
Febrile Neutropenia Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Febrile Neutropenia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Febrile Neutropenia and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Febrile Neutropenia.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Febrile Neutropenia companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Filgrastim Biosimilars
- Pegfilgrastim
- Pegfilgrastim Biosimilars
- Vancomycin Hydrochloride
- Others
Applications
- Hospitals
- Clinics
- Others
Companies covered
- BeyondSpring Inc.
- Eli Lilly and Company
- Taiho Pharmaceutical Co., Ltd.
- Amgen Inc.
- Xenetic Biosciences, Inc. (XBIO)
- USV Private Limited
- Richter Gedeon Nyrt.
- Hospira, Inc.
- Aequus BioPharma, Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Febrile Neutropenia Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Febrile Neutropenia Market Size by Region (2021-2032)
- 1.4.1 Global Febrile Neutropenia Market Size by Region (2021-2026)
- 1.4.2 Global Febrile Neutropenia Market Size by Region (2027-2032)
- 1.5 Key Regions Febrile Neutropenia Market Size (2021-2032)
- 1.5.1 North America Febrile Neutropenia Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Febrile Neutropenia Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Febrile Neutropenia Market Size Growth Rate (2021-2032)
- 1.5.4 South America Febrile Neutropenia Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Febrile Neutropenia Market Size Growth Rate (2021-2032)
2 Febrile Neutropenia Market by Type
- 2.1 Type Introduction
- 2.1.1 Filgrastim Biosimilars
- 2.1.2 Pegfilgrastim
- 2.1.3 Pegfilgrastim Biosimilars
- 2.1.4 Vancomycin Hydrochloride
- 2.1.5 Others
- 2.2 Global Febrile Neutropenia Market Size by Type
- 2.2.1 Global Febrile Neutropenia Market Size Overview by Type (2021-2032)
- 2.2.2 Global Febrile Neutropenia Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Febrile Neutropenia Market Size Forecasted by Type (2027-2032)
- 2.3 Global Febrile Neutropenia Market Size by Regions
- 2.3.1 North America Febrile Neutropenia Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Febrile Neutropenia Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Febrile Neutropenia Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Febrile Neutropenia Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Febrile Neutropenia Market Size Breakdown by Type (2021-2026)
3 Febrile Neutropenia Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospitals
- 3.1.2 Clinics
- 3.1.3 Others
- 3.2 Global Febrile Neutropenia Market Size by Application
- 3.2.1 Global Febrile Neutropenia Market Size Overview by Application (2021-2032)
- 3.2.2 Global Febrile Neutropenia Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Febrile Neutropenia Market Size Forecasted by Application (2027-2032)
- 3.3 Global Febrile Neutropenia Market Size by Regions
- 3.3.1 North America Febrile Neutropenia Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Febrile Neutropenia Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Febrile Neutropenia Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Febrile Neutropenia Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Febrile Neutropenia Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Febrile Neutropenia Industry Trends
- 4.2 Febrile Neutropenia Industry Drivers
- 4.3 Febrile Neutropenia Industry Opportunities and Challenges
- 4.4 Febrile Neutropenia Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Febrile Neutropenia Revenue (2021-2026)
- 5.2 Global Febrile Neutropenia Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Febrile Neutropenia Key Company Headquarters & Area Served
- 5.4 Global Febrile Neutropenia Company, Product Type & Application
- 5.5 Global Febrile Neutropenia Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Febrile Neutropenia Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Febrile Neutropenia Players Market Share by Revenue in 2025
- 5.6.3 2025 Febrile Neutropenia Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 BeyondSpring Inc.
- 6.1.1 BeyondSpring Inc. Company Information
- 6.1.2 BeyondSpring Inc. Business Overview
- 6.1.3 BeyondSpring Inc. Febrile Neutropenia Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 BeyondSpring Inc. Febrile Neutropenia Product Portfolio
- 6.1.5 BeyondSpring Inc. Recent Developments
- 6.2 Eli Lilly and Company
- 6.2.1 Eli Lilly and Company Company Information
- 6.2.2 Eli Lilly and Company Business Overview
- 6.2.3 Eli Lilly and Company Febrile Neutropenia Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Eli Lilly and Company Febrile Neutropenia Product Portfolio
- 6.2.5 Eli Lilly and Company Recent Developments
- 6.3 Taiho Pharmaceutical Co., Ltd.
- 6.3.1 Taiho Pharmaceutical Co., Ltd. Company Information
- 6.3.2 Taiho Pharmaceutical Co., Ltd. Business Overview
- 6.3.3 Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Product Portfolio
- 6.3.5 Taiho Pharmaceutical Co., Ltd. Recent Developments
- 6.4 Amgen Inc.
- 6.4.1 Amgen Inc. Company Information
- 6.4.2 Amgen Inc. Business Overview
- 6.4.3 Amgen Inc. Febrile Neutropenia Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Amgen Inc. Febrile Neutropenia Product Portfolio
- 6.4.5 Amgen Inc. Recent Developments
- 6.5 Xenetic Biosciences, Inc. (XBIO)
- 6.5.1 Xenetic Biosciences, Inc. (XBIO) Company Information
- 6.5.2 Xenetic Biosciences, Inc. (XBIO) Business Overview
- 6.5.3 Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Product Portfolio
- 6.5.5 Xenetic Biosciences, Inc. (XBIO) Recent Developments
- 6.6 USV Private Limited
- 6.6.1 USV Private Limited Company Information
- 6.6.2 USV Private Limited Business Overview
- 6.6.3 USV Private Limited Febrile Neutropenia Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 USV Private Limited Febrile Neutropenia Product Portfolio
- 6.6.5 USV Private Limited Recent Developments
- 6.7 Richter Gedeon Nyrt.
- 6.7.1 Richter Gedeon Nyrt. Company Information
- 6.7.2 Richter Gedeon Nyrt. Business Overview
- 6.7.3 Richter Gedeon Nyrt. Febrile Neutropenia Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Richter Gedeon Nyrt. Febrile Neutropenia Product Portfolio
- 6.7.5 Richter Gedeon Nyrt. Recent Developments
- 6.8 Hospira, Inc.
- 6.8.1 Hospira, Inc. Company Information
- 6.8.2 Hospira, Inc. Business Overview
- 6.8.3 Hospira, Inc. Febrile Neutropenia Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Hospira, Inc. Febrile Neutropenia Product Portfolio
- 6.8.5 Hospira, Inc. Recent Developments
- 6.9 Aequus BioPharma, Inc.
- 6.9.1 Aequus BioPharma, Inc. Company Information
- 6.9.2 Aequus BioPharma, Inc. Business Overview
- 6.9.3 Aequus BioPharma, Inc. Febrile Neutropenia Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Aequus BioPharma, Inc. Febrile Neutropenia Product Portfolio
- 6.9.5 Aequus BioPharma, Inc. Recent Developments
7 North America
- 7.1 North America Febrile Neutropenia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Febrile Neutropenia Market Size by Country (2021-2026)
- 7.3 North America Febrile Neutropenia Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Febrile Neutropenia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Febrile Neutropenia Market Size by Country (2021-2026)
- 8.3 Europe Febrile Neutropenia Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Febrile Neutropenia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Febrile Neutropenia Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Febrile Neutropenia Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Febrile Neutropenia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Febrile Neutropenia Market Size by Country (2021-2026)
- 10.3 South America Febrile Neutropenia Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Febrile Neutropenia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Febrile Neutropenia Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Febrile Neutropenia Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst